Clinical Trial Update: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the withdrawal of a rollover protocol studying elacestrant in combination with onapristone for ER-positive, PR-positive, HER2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)
• Onapristone (onapristone)

Snippet

Sponsor: Context Therapeutics Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN